Burroughs Wellcome's Lamictal
Executive Summary
Anti-epileptic is "approvable" as of July 26 as adjuvant therapy in the treatment of partial seizures in adults with epilepsy. Lamictal (lamotrigine) was recommended for approval by FDA's Peripheral & Central Nervous System Drugs Advisory Committee in March 1993